Hipscs-derived cardiomyocytes for cardiomyopathy therapy development
Fraunhofer IBMT offers hiPSCs-derived cardiomyocytes carrying cardiomyopathy-related mutations, enabling research and therapy development for heart diseases. These cardiomyocytes are validated for various assays and are ready for further characterization and application.
Overview
Fraunhofer IBMT provides human induced pluripotent stem cells (hiPSCs) and derived cardiomyocytes carrying mutations associated with cardiomyopathy. These specialized cell lines offer a unique opportunity for research and development in heart disease therapies. The cardiomyocytes are derived from hiPSCs containing mutations in genes such as MYBP3, MYH7, RYR2, and TNNT2, which are known to influence cardiomyopathy. This resource supports pharmaceutical companies like Bayer in developing targeted therapies for these conditions.
Technical specifications
Fraunhofer IBMT has established robust protocols for differentiating hiPSCs into cardiomyocytes, ensuring high-quality and reproducible results. The technology includes industry-standard practices for cell culture, expansion, and quality control under Good Laboratory Practice (GLP) conditions. Key technical features include:
- Differentiation protocols validated with multiple hiPS lines
- Large-scale cardiomyocyte generation in bioreactors
- Cryopreservation and quality control of cardiomyocytes
- Assay readiness for microelectrode array recordings, calcium transient recordings, and other advanced analyses
- Comprehensive support for characterization through various readouts, including MEA, EHT contraction, Seahorse analysis, HCS immunochemistry, life cell imaging, qPCR, and FACS analyses
Technology readiness level
The technology is at TRL 4, indicating that it has been validated in a laboratory setting. Fraunhofer IBMT continues to refine differentiation protocols and characterization techniques to ensure scalability and applicability in therapeutic development.
About Fraunhofer Institute
Fraunhofer is a large, multi-site applied research organization based in Germany, operating a nationwide network of institutes and research units with a strong industry-facing mission. Its contract-research model aligns work to real manufacturing and deployment needs, with pilot lines, test labs, and demonstration facilities for validation and scale-up. Many institutes are integrated with nearby universities and regional industry clusters, enabling joint appointments, shared infrastructure, and fast talent pipelines. Research is supported by competitive European programs alongside German federal and state funding, complemented by extensive contract revenue from private-sector collaborations. A dedicated technology transfer function manages IP, licensing, and startup formation.
delivered to your inbox.